Peptides for Weight Loss Research — GLP-1, GH Fragment & Metabolic Compounds | QSC

QSC RESEARCH COMPOUND GUIDE
GLP-1R AgonistTriple AgonistGH FragmentLipotropicFat OxidationMetabolic Research

Condition overview: peptides and research compounds targeting adipose metabolism, energy expenditure, appetite regulation, and body composition in preclinical and clinical research models.

Weight Loss Research — Overview

How research compounds act on adipose tissue, appetite, and energy expenditure

Obesity and metabolic dysfunction are among the most studied areas in peptide research. Research compounds targeting weight loss operate through three primary mechanisms: (1) incretin-mediated appetite suppression via GLP-1R, GIPR, and GCGR agonism, (2) direct lipolysis via GH axis modulation, and (3) mitochondrial uncoupling and energy expenditure enhancement. QSC stocks compounds spanning all three pathways.

Mechanism Pathway Primary Compounds Research Evidence
GLP-1R agonism Reduces appetite, slows gastric emptying, increases insulin secretion Semaglutide, Liraglutide, Orforglipron Phase 3 RCT data (STEP, SCALE, SURMOUNT trials)
Dual GIP+GLP-1R agonism Adds GIP receptor for enhanced insulin + GLP-1 appetite effects Tirzepatide, Cagrilintide + Semaglutide SURMOUNT-1: 22.5% mean weight reduction
Triple GLP-1R/GIPR/GCGR agonism Adds glucagon receptor for direct hepatic fat mobilisation Retatrutide, Survodutide Phase 2: 24.2% weight reduction at 48 weeks
GH axis / lipolysis Selective GHR C-terminal fragment activates lipolysis without anabolic IGF-1 effects HGH Fragment 176-191, AOD-9604 DIO mouse models: significant fat mass reduction vs vehicle
Mitochondrial uncoupling Proton gradient disruption increases basal energy expenditure BAM15, DNP C57BL/6 models: thermogenesis without hyperthermia (BAM15)
Lipotropic blend MIC triad + L-Carnitine supports hepatic fat export and mitochondrial fatty acid import Lipo-C In vitro hepatocyte models: TG reduction, VLDL secretion

GLP-1 / Incretin Class

Highest-evidence compounds for weight loss research

Semaglutide

GLP-1R AgonistOnce-WeeklyPhase 3 RCT DataOzempic / Wegovy analog

Mechanism GLP-1R agonist. Fatty acid acylation enables once-weekly dosing (t½ ~168h). Reduces caloric intake via hypothalamic GLP-1R signalling, slows gastric emptying, increases insulin secretion.
Research Model DIO C57BL/6 mice, Zucker fa/fa rats, human STEP trial cohorts
Key Readouts Body weight %, fat mass (EchoMRI), food intake, fasting glucose, HbA1c, GLP-1R expression
Tirzepatide

Dual GIP+GLP-1RPhase 3 DataMounjaro/Zepbound analogSURMOUNT trial

Mechanism Dual GIP+GLP-1R agonist. Single peptide activates both incretin receptors. GIP component adds direct adipocyte lipid metabolism modulation beyond GLP-1 alone.
Research Model DIO mouse, ob/ob mouse, human SURMOUNT-1 phase 3
Key Readouts Weight %, fat mass, lean mass, GTT, ITT, lipid panel, cardiovascular markers
Retatrutide

Triple AgonistGLP-1R / GIPR / GCGRPhase 2 RCT24.2% weight reduction

Mechanism Triple GLP-1R/GIPR/GCGR agonist. GCGR component adds direct hepatic gluconeogenesis suppression and brown adipose tissue activation beyond dual agonists.
Research Model Phase 2 RCT (N=338, 48 weeks), DIO mouse models
Key Readouts Weight reduction %, liver fat (MRI-PDFF), visceral fat, cardiovascular risk markers, tolerability
Cagrilintide

Amylin AnalogArea PostremaCagriSema ComboComplementary to GLP-1

Mechanism Long-acting amylin analog. Acts on area postrema and NTS to reduce meal size and frequency via complementary mechanism to GLP-1R agonism.
Research Model CagriSema Phase 2 combo trial, amylin receptor knockout models
Key Readouts Appetite scores, meal frequency, body weight %, complementary effects with semaglutide
Orforglipron

Oral GLP-1RNon-PeptideNo InjectionPhase 2 Data

Mechanism Oral non-peptide GLP-1R agonist. Small molecule, no injection required. Overcomes peptide bioavailability limitations via oral route.
Research Model Phase 2 GZGI trial, oral bioavailability models, DIO mouse
Key Readouts Oral bioavailability %, body weight %, GLP-1R binding affinity vs semaglutide, HbA1c

GH Axis / Direct Lipolysis

GH-derived compounds targeting adipose tissue directly

HGH Fragment 176-191

GH FragmentSelective LipolysisNo IGF-1 EffectAdipose-Targeted

Mechanism C-terminal fragment of HGH (aa 176-191). Activates lipolysis via GHR without triggering anabolic IGF-1 axis. Selective adipose effect.
Research Model DIO C57BL/6 mice, in vitro adipocyte lipolysis assay, GHR knockout controls
Key Readouts Fat mass (EchoMRI), lean mass (unchanged), IGF-1 (unchanged), FFA release, adiponectin
AOD-9604

Modified GH FragmentPhase 2 Human DataAnti-Obesity Drug CandidateLipolysis

Mechanism Modified HGH Fragment 177-191. Anti-obesity drug candidate (Metabolic Pharmaceuticals). Additional stabilisation vs native fragment.
Research Model DIO mouse, Phase 2 human trial (obese subjects), adipocyte culture
Key Readouts Body fat %, waist circumference, visceral fat (DXA), metabolic rate (indirect calorimetry)
Tesamorelin

GHRH AnalogFDA-Approved EgriftaVisceral FatHIV Lipodystrophy Model

Mechanism GHRH analog. Stimulates endogenous GH pulse. FDA-approved (Egrifta) for HIV-associated lipodystrophy — visceral fat reduction in clinical setting.
Research Model HIV-lipodystrophy patients, DIO mouse, GHRH receptor models
Key Readouts Visceral fat (MRI), trunk fat %, IGF-1, GH pulse amplitude, triglycerides

Lipotropic & Mitochondrial

Hepatic fat export and energy expenditure compounds

Lipo-C Blend

LipotropicMIC + L-CarnitineHepatic Fat ExportB12 + Glutathione

Mechanism Multi-component lipotropic blend: methionine + inositol + choline (MIC) + L-carnitine + B-vitamin complex + glutathione. Addresses hepatic fat export (VLDL assembly), mitochondrial fatty acid import (CPT1/carnitine), and oxidative stress.
Research Model HFD-induced NAFLD mouse (C57BL/6), primary hepatocyte MCD model, body composition DIO mouse
Key Readouts Liver TG, NAS histology score, VLDL-TG output, ApoB ELISA, EchoMRI fat mass, RER, GTT
5-Amino-1MQ

NNMT InhibitorNAD+ PathwaySIRT1 ActivationFat Oxidation

Mechanism NNMT (nicotinamide N-methyltransferase) inhibitor. NNMT consumes SAM methyl groups and reduces NAD+ availability. Inhibition raises intracellular NAD+, activates SIRT1, promotes fat oxidation.
Research Model DIO C57BL/6, NNMT knockout comparison, adipocyte culture, NAD+ flux models
Key Readouts Body weight %, fat mass, NNMT activity, NAD+/NADH ratio, SIRT1 expression, UCP1

Research Protocols

Standard experimental designs for weight loss compound research

Protocol A: DIO Mouse Body Composition Study

Step Detail
Model C57BL/6 male mice, high-fat diet (60% kcal fat) × 12 weeks induction
Groups Vehicle control | Compound dose 1 | Compound dose 2 | Positive control (semaglutide 60nmol/kg)
Administration SC injection, 3× weekly or daily depending on compound half-life
Duration 8–12 weeks treatment
Primary readouts EchoMRI body composition (fat mass, lean mass) at baseline, week 4, week 8
Secondary readouts Food intake, body weight weekly, GTT (week 6), ITT (week 8), fasting insulin, leptin
Terminal Liver weight, liver TG, adipose tissue weight (inguinal, epididymal, brown), histology H&E

Protocol B: GLP-1R Agonist Dose-Response

Step Detail
Model DIO C57BL/6 or Zucker fa/fa rats for insulin resistance phenotype
Design Dose escalation: 3, 10, 30, 100 nmol/kg SC to establish ED50
Endpoints Food intake (24h and 48h post-dose), body weight, GLP-1R binding (autoradiography)
Controls GLP-1R knockout mice as negative control, exendin-4 as positive reference
Duration Acute (single dose PK/PD) followed by 4-week chronic study at ED50

Frequently Asked Questions

What peptides are most researched for weight loss?

The highest-evidence compounds are the GLP-1R agonist class — semaglutide, tirzepatide, and retatrutide. These have Phase 2 and Phase 3 human clinical trial data demonstrating 15-24% body weight reduction. For preclinical research, HGH Fragment 176-191, AOD-9604, and 5-Amino-1MQ are commonly used in DIO mouse models.

What is the difference between semaglutide, tirzepatide, and retatrutide?

Semaglutide is a single GLP-1R agonist. Tirzepatide adds GIP receptor agonism (dual agonist), producing greater weight reduction. Retatrutide adds a third mechanism — glucagon receptor agonism — making it a triple agonist with the highest weight reduction observed in Phase 2 trials (24.2% at 48 weeks). Each step adds a complementary mechanism rather than simply increasing dose.

Do GH peptides like HGH Fragment 176-191 cause weight loss the same way as GLP-1 peptides?

No — the mechanisms are distinct. GLP-1 peptides suppress appetite centrally via hypothalamic receptors. HGH Fragment 176-191 works peripherally by activating lipolysis in adipocytes without affecting appetite or the GH anabolic axis. They can be studied in combination in research models as they target different pathways.

What QSC compounds does the research literature support for visceral fat reduction specifically?

Tesamorelin has the strongest evidence for visceral fat — FDA-approved for HIV lipodystrophy with MRI-confirmed visceral fat reduction. Retatrutide Phase 2 data showed significant reductions in liver fat (MRI-PDFF). Semaglutide STEP trials documented trunk fat reduction. AOD-9604 Phase 2 data showed waist circumference and visceral fat reduction in obese subjects.

Does QSC ship weight loss research peptides to the USA?

Yes. All compounds on this page — semaglutide, tirzepatide, retatrutide, HGH Fragment 176-191, AOD-9604, tesamorelin, Lipo-C, and 5-Amino-1MQ — are available with domestic USA shipping. All products carry Janoshik third-party COA confirming ≥99% HPLC purity and MS identity verification.

Related Research Areas

Tissue Recovery |
Longevity |
Cognitive |
Sleep |
Sexual Health



Research Use Only: All QSC compounds are sold strictly for laboratory research purposes. Not for human use.
Peptides
Orals
Oils
Search
Contact